Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress’ Oxycontin concerns continue

Executive Summary

Reps. Frank Wolf (R-Va), Jim Greenwood (R- Pa), Henry Bonilla (R-Texas) and Harold Rogers (R- Ky) meet with FDA Commissioner McClellan April 3 to discuss abuse of Purdue's OxyContin (oxycodone). Wolf sent a letter to HHS Secretary Thompson March 28 asking that OxyContin treatment be limited to patients with severe pain. The House Energy & Commerce committee is investigating OxyContin and Purdue's Palladone, a pain therapy pending at FDA (1"The Pink Sheet" March 3, p. 33)...

You may also be interested in...

Purdue Palladone Risk Management Documents Requested By House Cmte.

Purdue Pharma will submit documents relating to risk management for its pending pain therapy Palladone to the House Energy & Commerce Committee

Advanz Pharma Agrees Sale In Largest European Deal Since COVID-19 Pandemic

Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.

Consumer Genome Sequencing Being Applied To Covid-19 New Variants In UK

The goal is to create a program which mass sequences SARS-CoV-2 samples in order to detect new variants, with £30m injected into the UK's hub for genomic sequencing in Cambridge.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts